Pharma Tech

Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead

Aug 6, 2026, 1:11 PM

Read Full Article → Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead

Translate article text

Choose a language and wait for the translated text.

GlobalData previously flagged Orzeyful’s approval in narcolepsy as a key Q3 catalyst for pharma due to the drug’s ‘transformative’ potential.